[Is the recommended treatment for erectile dysfunction effective for men over age 65?].

Prog Urol

Département d'urologie-andrologie, hôpital Robert-Debré, CHU de Reims, avenue Général-Koënig, 51092 Reims cedex, France.

Published: March 2009

Objectives: To evaluate the recommended erectile dysfunction treatment algorithm for men over age 65.

Patients And Methods: Between 2004 and 2006, 334 men were treated for ED at our institution, of whom 64 were greater than 65 years old (19.2%). Medical history, ED treatments and patients' satisfaction were reported. The first line therapy was PDE 5 inhibitors except after radical prostatectomy, followed by intracavernous injections (ICI). When conservative treatments failed, penile prosthesis was proposed. Mean follow up was 23.7 months.

Results: Mean age was 69.2 years (65-81). Aetiology of ED was organic in 85.9% (39.1% after radical pelvic surgery) and partially drug induced in 45.8%. With PDE 5 inhibitors, the mean success rate was 26.5 and 7.1% after radical pelvic surgery. Because of cost, 30.8 % of satisfied patients stopped PDE 5 inhibitors. Mean ICI success rate was 60.4% but 34.5% of satisfied men interrupted them. Finally, 14% of patients were successfully treated by PDE 5 inhibitors and 29.7% by ICI. Penile prosthesis was implanted in 12 patients (18.7%) with a mean success rate of 83.3%. No successful ED treatment was found in a third of patients.

Conclusion: PDE 5 inhibitors after 65 were found to be less successful as envisaged. This study points out the probable inadequacy between the patients' expectations and the therapeutic options, including socioeconomic terms.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2008.11.010DOI Listing

Publication Analysis

Top Keywords

pde inhibitors
20
success rate
12
erectile dysfunction
8
men age
8
penile prosthesis
8
radical pelvic
8
pelvic surgery
8
pde
5
inhibitors
5
[is recommended
4

Similar Publications

Background And Aim: In the context of gastrointestinal diseases, the role of monoacylglycerol lipase (MAGL) is significant. Therefore, the objective of this study was to examine the protective effects of MAGL inhibition using JZL184 in rat models of severe acute pancreatitis (SAP) and to explore its mechanism.

Methods: In this study, a rat model of SAP was established, and the rats were divided into three groups for treatment: the Control group (CON), the SAP group (SAP), and the SAP group treated with JZL184 (JZL184).

View Article and Find Full Text PDF

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Biomed Pharmacother

January 2025

Laboratory for Functional Imaging & Research on Stem Cells, BIOMED, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. Electronic address:

Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited peripheral neuropathy caused by a duplication of the peripheral myelin protein 22 (PMP22) gene. It is primarily marked by Schwann cell dedifferentiation and demyelination, leading to motor and sensory deficits. Cyclic adenosine monophosphate (cAMP) is crucial for Schwann cell differentiation and maturation.

View Article and Find Full Text PDF

In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia.

Clin Psychopharmacol Neurosci

February 2025

Department of Mental Health of Enna, Psychiatry Unity, Enna Hospital, Enna, Italy.

Intracellular cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanosine monophosphate) and downstream cellular signal transduction are regulated by phosphodiesterases (PDEs). The neuroplasticity, neurotransmitter pathways, and neuroinflammation-controlling functions of PDEs were demonstrated in numerous in vitro and animal model studies. We comprehensively reviewed the literature regarding the expression of PDEs in various brain regions.

View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease that lacks effective therapy. The overexpression of phosphodiesterase 10A (PDE10A) plays a vital role in pulmonary fibrosis (PF). However, the impact of selective PDE10A inhibitors on the tumor growth factor-β (TGF-β)/small mother against decapentaplegic (Smad) signaling pathway remains unclear.

View Article and Find Full Text PDF

Discovery of a Phosphodiesterase 7A Inhibitor of High Isozyme Selectivity Exhibiting Anti-Osteoporotic Effects.

ACS Med Chem Lett

January 2025

Chemical Research Laboratories, i2i-Labo, Biological Pharmacological Research Laboratories, and Drug Metabolism & Pharma-cokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco, Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.

Phosphodiesterases (PDEs) have drawn attention due to their critical roles in physiological and pathological conditions. Many research groups have studied these hydrolytic enzymes to develop new drugs, including apremilast as a PDE4 inhibitor and sildenafil as a PDE5 inhibitor. Targeting PDE7 has also been deemed a rational strategy to ameliorate autoimmune conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!